LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Kala Pharmaceuticals Inc

Fermé

0.49 -15.52

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.44

Max

0.6

Chiffres clés

By Trading Economics

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+154.24% upside

Kala Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 déc. 2025, 23:54 UTC

Actions en Tendance

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 déc. 2025, 23:51 UTC

Résultats

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 déc. 2025, 23:39 UTC

Principaux Mouvements du Marché

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 déc. 2025, 22:57 UTC

Acquisitions, Fusions, Rachats

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 déc. 2025, 21:40 UTC

Résultats

Nike Sales Tick Up, But China Weakness Persists

18 déc. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 déc. 2025, 23:37 UTC

Market Talk
Résultats

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 déc. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 déc. 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 déc. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 déc. 2025, 23:00 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 déc. 2025, 22:59 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 déc. 2025, 22:58 UTC

Acquisitions, Fusions, Rachats

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 déc. 2025, 22:57 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 déc. 2025, 22:56 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 déc. 2025, 22:55 UTC

Résultats

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 déc. 2025, 21:59 UTC

Résultats

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 déc. 2025, 21:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 déc. 2025, 21:35 UTC

Résultats

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 déc. 2025, 21:31 UTC

Résultats

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Greater China Rev Down 17% >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q EPS 53c >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Apparel Rev $3.91B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Equipment Rev $550M >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q N Amer Rev $5.63B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Footwear Rev $7.66B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Greater China Rev $1.42B >NKE

Comparaison

Variation de prix

Kala Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

154.24% hausse

Prévisions sur 12 Mois

Moyen 1.5 USD  154.24%

Haut 1.5 USD

Bas 1.5 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

2 ratings

0

Achat

2

Maintien

0

Vente

Éléments financiers

$

À Propos Kala Pharmaceuticals Inc

Kala Pharmaceuticals Inc
help-icon Live chat